Lotus Pharmaceuticals

Lotus Pharmaceuticals is owned by Alvogen. Alvogen has a direct presence in 4 countries.

Alvogen has 5 subsidiaries including Adalvo, Alvogen Americas and Alvogen APAC.

They are in:

• Pharmaceuticals83%
• Biotechnology17%

View the org chart displaying its 26 main executives

Most searched biographies at Lotus Pharmaceuticals

• Petar Vazharov, General Manager and Director
• Krisana Winitthumkul, Director
• Yves Hermes, Director

Create your alert
to follow the executive moves at Lotus Pharmaceuticals.

Alvogen has 1,868 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).
• Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director at Dirk Rossmann
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma

Learn more about the Pharmaceuticals industry >

Press releases by Lotus Pharmaceuticals

• Lotus marked historical high for 2023 revenues, profit and cash dividend - Lotus
• Lotus Reported Unaudited February Revenues of NT$1,052 Million - Lotus
• Lotus Reported Unaudited January Revenues of NT$1,996 Million, surging 45.4% MoM - Lotus
• Lotus Reported Unaudited December Consolidated Revenues of NT$1,372 million, showcasing MoM and YoY Growth 2023 Unaudited Consolidated Revenues Grew 16% to NT$16,958 million, marking 5th consecutive year of double-digit growth - Lotus
• Lotus and Favorex Pte Ltd Announces Strategic Partnership to Commercialize an Ustekinumab Biosimilar in South Korea - Lotus
• Lotus Pharmaceutical Announces First Shipment of Lenalidomide to Japan - Lotus
• Lotus Achieves Historic Q3 2023 Results with YTD EPS Soaring to a Record NTD 14.19 Marking a 29% Year-on-Year Growth - Lotus
• Lotus and Intas Announce Strategic Partnership to Commercialize Denosumab Biosimilar in Asia - Lotus
• Lotus Reported Unaudited November Consolidated Revenues of NT$1,135 million, representing 25% MoM Growth and 6% YoY Growth - Lotus
• Lotus Hosts Third Quarter 2023 Results Investor Conference - Lotus
• View more press releases Close

Social media about Lotus Pharmaceuticals

• Lotus Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Lotus Pharmaceuticals on LinkedIn, Twitter & YouTube

Contact by email its executives including Petar Vazharov

Call Lotus Pharmaceuticals at +886 22...

View the org chart

Register to receive your alert

Report an error